Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients
Abstract Multiple myeloma (MM) patients are at risk of fatal outcome after SARS-CoV-2 infection. Preliminary data suggest that MM patients have an impaired response to vaccination. This prospective study analyzed the humoral and cellular immune responses to two doses of BNT162b2 in 72 MM patients, including 48 receiving anti-CD38 immunotherapy. Results evidenced that MM patients display lower levels of SARS-CoV-2 specific IgG and IgA antibodies and decreased neutralization of alpha and delta variants when compared to healthy controls. They also showed decreased numbers of circulating IFNγ-producing Spike SARS-CoV-2 specific T lymphocytes. This defective immune response was particularly marked in patients receiving anti-CD38 immunotherapy. Furthermore, a retrospective investigation of MM patients among COVID-19-related death in the Paris area suggested a limited efficacy of BNT162b2 in patients treated with anti-CD38. Overall, these results show a decreased immunogenicity of BNT162b2 in MM patients and stress the need for novel strategies to improve SARS-CoV-2 prophylaxis in immunocompromised individuals..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
bioRxiv.org - (2023) vom: 07. Jan. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Henriquez, S. [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
---|
doi: |
10.1101/2021.08.08.21261769 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI032351453 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI032351453 | ||
003 | DE-627 | ||
005 | 20230429085426.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210810s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2021.08.08.21261769 |2 doi | |
035 | |a (DE-627)XBI032351453 | ||
035 | |a (biorXiv)10.1101/2021.08.08.21261769 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Henriquez, S. |e verfasserin |4 aut | |
245 | 1 | 0 | |a Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Multiple myeloma (MM) patients are at risk of fatal outcome after SARS-CoV-2 infection. Preliminary data suggest that MM patients have an impaired response to vaccination. This prospective study analyzed the humoral and cellular immune responses to two doses of BNT162b2 in 72 MM patients, including 48 receiving anti-CD38 immunotherapy. Results evidenced that MM patients display lower levels of SARS-CoV-2 specific IgG and IgA antibodies and decreased neutralization of alpha and delta variants when compared to healthy controls. They also showed decreased numbers of circulating IFNγ-producing Spike SARS-CoV-2 specific T lymphocytes. This defective immune response was particularly marked in patients receiving anti-CD38 immunotherapy. Furthermore, a retrospective investigation of MM patients among COVID-19-related death in the Paris area suggested a limited efficacy of BNT162b2 in patients treated with anti-CD38. Overall, these results show a decreased immunogenicity of BNT162b2 in MM patients and stress the need for novel strategies to improve SARS-CoV-2 prophylaxis in immunocompromised individuals. | ||
650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
700 | 1 | |a Zerbit, J. |e verfasserin |4 aut | |
700 | 1 | |a Bruel, T. |e verfasserin |4 aut | |
700 | 1 | |a Ouedrani, A. |e verfasserin |4 aut | |
700 | 1 | |a Planas, D. |e verfasserin |4 aut | |
700 | 1 | |a Deschamps, P. |e verfasserin |4 aut | |
700 | 1 | |a Staropoli, I. |e verfasserin |4 aut | |
700 | 1 | |a Hadjadj, J. |e verfasserin |4 aut | |
700 | 1 | |a Varet, B. |e verfasserin |4 aut | |
700 | 1 | |a Suarez, F. |e verfasserin |4 aut | |
700 | 1 | |a Ermark, N. |e verfasserin |4 aut | |
700 | 1 | |a Bouscary, D. |e verfasserin |4 aut | |
700 | 1 | |a Willems, L. |e verfasserin |4 aut | |
700 | 1 | |a Fouquet, G. |e verfasserin |4 aut | |
700 | 1 | |a Decroocq, J. |e verfasserin |4 aut | |
700 | 1 | |a Franchi, P. |e verfasserin |4 aut | |
700 | 1 | |a Deau-Fischer, B. |e verfasserin |4 aut | |
700 | 1 | |a Terrier, B. |e verfasserin |4 aut | |
700 | 1 | |a Tamburini, J. |e verfasserin |4 aut | |
700 | 1 | |a Chatenoud, L. |e verfasserin |4 aut | |
700 | 1 | |a Schwartz, O. |e verfasserin |4 aut | |
700 | 1 | |a Vignon, M. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 07. Jan. |
773 | 1 | 8 | |g year:2023 |g day:07 |g month:01 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.08.08.21261769 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2023 |b 07 |c 01 |